Latest Intellectual Property News

Biome Australia Limited reports its first profitable year since 2018, driven by a 41.6% revenue increase and significant international growth.

PlaySide reports a 25% revenue decline and a $12.1 million net loss in FY25, driven by fewer original IP launches and restructuring costs. The company raises capital and streamlines operations ahead of major 2026 game releases.

PlaySide Studios reported a significant revenue drop and EBITDA loss in FY25, driven by declines in original IP sales. However, the company is banking on new game launches and cost-cutting measures to fuel a turnaround in FY26.

PlaySide Studios reported a 25% revenue decline to $48.7 million for FY25, resulting in a $12.1 million net loss. The company is banking on new game launches and cost savings to reverse the downturn in FY26.

Terragen Holdings reported a $3.72 million loss for FY25, impacted by drought and lower revenues, while launching dry probiotic products targeting feedlots and completing a $4.76 million equity raise.

Cleo Diagnostics reported a $4 million loss for FY2025 while making significant strides toward FDA approval of its novel ovarian cancer blood test. The company is progressing clinical trials and scaling manufacturing in preparation for market entry.

Race Oncology Limited reported a significantly reduced loss for FY2025, driven by key clinical trial progress and strategic leadership changes. The company advances its RC220 program with promising Phase 1 dosing milestones and strengthens its governance to support future growth.

Hazer Group has reported a remarkable FY25 performance with revenues more than doubling and losses slashed by 60%, underpinned by a strategic partnership with KBR and early commercial revenues.

Hazer Group Limited reported a 124% surge in revenues to $8.5 million for FY25, driven by government grants, while cutting its net loss by 60%. The company advanced its proprietary methane pyrolysis technology, secured a strategic alliance with KBR, and made progress on key projects in Canada and Japan.

Neurizon Therapeutics reported a $16.6 million loss for FY2025 amid significant progress in its lead neurodegenerative therapy NUZ-001, including regulatory milestones and a global licensing deal. The company is poised to enter a pivotal ALS clinical trial pending FDA clearance.

Calix Limited reported solid FY25 results with 17% growth in product revenue, a 23% cut in operating costs, and an extended 18-month cash runway, while progressing key decarbonisation projects.

Bio-Gene Technology Limited reported a net loss of AUD 2.58 million for FY2025 while making significant strides in developing its bio-insecticides Flavocide and Qcide, securing US Department of Defense grants and expanding global partnerships.